 Heres a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks Biotech Stocks Hitting 52-week Highs June 23 ACADIA Pharmaceuticals Inc. NASDAQ: ACAD Acceleron Pharma Inc NASDAQ: XLRN ADC Therapeutics SA NYSE: ADCT Adverum Biotechnologies Inc NASDAQ: ADVM Aeglea Bio Therapeutics Inc NASDAQ: AGLE Alnylam Pharmaceuticals, Inc. NASDAQ: ALNY Amicus Therapeutics, Inc. NASDAQ: FOLD Ascendis Pharma AS NASDAQ: ASND Avidity Biosciences Inc NASDAQ: RNA went public June 12 BioXcel Therapeutics Inc NASDAQ: BTAI Burning Rock Biotech Ltd NASDAQ: BNR went public June 12 Corcept Therapeutics Incorporated NASDAQ: CORT Crispr Therapeutics AG NASDAQ: CRSP moved on analyst action Dr.Reddys Laboratories Ltd NYSE: RDY Dyadic International, Inc. NASDAQ: DYAI Editas Medicine Inc NASDAQ: EDIT GENMAB ASS ADR NASDAQ: GMAB Halozyme Therapeutics, Inc. NASDAQ: HALO Hologic, Inc. NASDAQ: HOLX Horizon Therapeutics PLC NASDAQ: HZNP Immunomedics, Inc. NASDAQ: IMMU Immunovant Inc NASDAQ: IMVT Incyte Corporation NASDAQ: INCY Innoviva Inc NASDAQ: INVA Inovio Pharmaceuticals Inc NASDAQ: INO announced DoD funding for coronavirus vaccine delivery device Inspire Medical Systems Inc NYSE: INSP Intellia Therapeutics Inc NASDAQ: NTLA ITAMAR MED LTDS ADR NASDAQ: ITMR Keros Therapeutics Inc NASDAQ: KROS KITOV PHARMA LTS ADR NASDAQ: KTOV announced a 35-million registered direct offering Legend Biotech Corp NASDAQ: LEGN went public June 5 Liquidia Technologies Inc NASDAQ: LQDA MacroGenics Inc NASDAQ: MGNX MannKind Corporation NASDAQ: MNKD MEI Pharma Inc NASDAQ: MEIP Meridian Bioscience, Inc. NASDAQ: VIVO Mersana Therapeutics Inc NASDAQ: MRSN Momenta Pharmaceuticals, Inc. NASDAQ: MNTA Myovant Sciences Ltd NYSE: MYOV announced positive results for a combo treatment involving its relugolix in endometriosis-related pain Neoleukin Therapeutics Inc NASDAQ: NLTX Neurocrine Biosciences, Inc. NASDAQ: NBIX Novavax, Inc. NASDAQ: NVAX Novo Nordisk AS NYSE: NVO Passage Bio Inc NASDAQ: PASG Pliant Therapeutics Inc NASDAQ: PLRX ResMed Inc. NYSE: RMD Sanofi SA NASDAQ: SNY - announced an accelerated timeline for its co-developed COVID-19 vaccine and an expanded partnership with Translate Bio Inc NASDAQ: TBIO for RNA vaccine research Sarepta Therapeutics Inc NASDAQ: SRPT Satsuma Pharmaceuticals Inc NASDAQ: STSA Seattle Genetics, Inc. NASDAQ: SGEN Spero Therapeutics Inc NASDAQ: SPRO Translate Bio moved on expanded pact with Sanofi Trevena Inc NASDAQ: TRVN Twist Bioscience Corp NASDAQ: TWST Ultragenyx Pharmaceutical Inc NASDAQ: RARE Vertex Pharmaceuticals Incorporated NASDAQ: VRTX Y-mAbs Therapeutics, Inc NASDAQ: YMAB Zai Lab Ltd NASDAQ: ZLABDown In The Dumps Biotech Stocks Hitting 52-week Lows June 23 Evofem Biosciences Inc NASDAQ: EVFM Genetron Holdings Ltd - ADR NASDAQ: GTH went public Friday Lyra Therapeutics Inc NASDAQ: LYRAStocks In Focus MediciNova Announces Receipt of Intent To Grant European Patent For Lipid-Lowering Drug MediciNova, Inc. NASDAQ: MNOV said it has received a notice of intention to grant from the European Patent Office for a pending patent application that covers MN-001 and MN-002 for the treatment of hypertriglyceridemia, hypercholesterolemia and hyperlipoproteinemia.The patent pertains to a method of reducing a triglyceride blood level, a method of reducing total cholesterol blood level and a method of reducing a low-density lipoprotein blood level using MN-001 or MN-002The patent is expected to expire no earlier than 2034 from the date of issuance.As we already have granted patents for similar indications in the U.S., Japan, and China, we believe this additional patent in Europe could substantially increase the potential value of MN-001, MediciNova CEO Yuichi Iwaki said in a statement.The stock added 14.68 to 6.25 in after-hours trading.GW Pharmas Epidyolex Moves To Low Level Of Control In UK GW Pharmaceuticals PLC- ADR NASDAQ: GWPH said the the U.K. Home Office has reclassified Epidyolex as a Schedule 5 drug, with the change taking effect immediately in all four constituent nations of the U.K.The decision to move EPIDYOLEX to a low level of control is an important one for patients, their families, healthcare professionals, pharmacists and the NHS as a whole - reducing costs and ensuring the medicine can be dispensed more easily, Chris Tovey, GW Pharmas chief operating officer, said in a statement. See also: The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Tela Bio Expects Revenue Decline In June Quarter, Plans Offering TELA Bio Inc NASDAQ: TELA said in a 8-K filing with the SEC that it expects revenue of between 2.1 million and 2.3 million for the quarter ended June 15, reflecting the adverse impact of decreased procedure volumes as a result of the deferral of elective procedures and corresponding reduced sales of units of OviTex products in the wake of the COVID-19 pandemic.The company expects a net loss of 5.5 million to 5.7 million.Analysts on average estimate a loss of 59 cents per share on revenue of 1.86 million.View more earnings on IBBSeparately, the company said it has commenced a proposed underwritten public offering of 3 million shares of its common stock. All the shares are being offered by the company.In after-hours trading, the stock fell 6.06 to 20.Regeneron Loses Antibody Patent Case Against Kymab U.K.-based biopharma Kymab said the Supreme Court of the U.K. has held that all of the claims of two patents owned by Regeneron Pharmaceuticals Inc NASDAQ: REGN that were asserted against Kymab are invalid.The patents in question cover genetically modified mice containing chimeric human-mouse antibody genes and the human antibodies made using such mice.The Courts decision upholds a February 2016 decision of the High Court to revoke the claims and reverses the Appeal Courts determination that they were valid, Kymab said.FDA Lifts Partial Clinical Hold On Innate Pharmas Blood Cancer Study Innate Pharma SA NASDAQ: IPHA said the FDA has lifted the partial clinical hold placed on the lacutamab TELLOMAK Phase 2 clinical trial.The trial is to evaluate the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas.The decision follows a quality assessment of a new Good Manufacturing Practice-certified batch that has been successfully manufactured for the lacutamab clinical development program.In the wake of the decision, the company said it is taking the operational measures to re-activate U.S. clinical trial sites.Imaras IMR-687 Receives Orphan Drug Designation For Beta-Thalassemia Imara Inc NASDAQ: IMRA said the FDA has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia. The agency had previously granted Orphan Drug Designation for IMR-687 for the treatment of patients with sickle cell disease.Offerings Editas said it has priced its underwritten offering of 6 million shares of its common stock at 31.25 per share for gross proceeds of about 187.5 million. The offering is expected to close on or about June 26.The stock slipped 5.68 to 32.39 in after-hours trading.Soleno Therapeutics Inc NASDAQ: SLNO said it intends to offer and sell shares of its common stock in an underwritten public offering.The stock was down 5.5 premarket Wednesday.On The Radar Clinical Readouts, Presentations Insmed Incorporated NASDAQ: INSM is due to present at the American Thoracic Society 2020 Virtual: Clinical Trials Session, Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 administered once daily in adults with non-cystic fibrosis bronchiectasis.Related Link: Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug See more from Benzinga The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragens Positive Readout The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 